Biogen Pharmachem Industries Ltd Financials
Company Logo

Biogen Pharmachem Industries Ltd Financial Statement

Biogen Pharmachem Industries Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Sep 2024
Revenue-0.65
Operating Expense0.35
Net Profit-1.00
Net Profit Margin153.85
Earning Per Share-0.02
EBIDTA-1.00
Effective Tax RateTBA

Biogen Pharmachem Industries Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue AnnualTBA
Operating Expenses Annual0.45
Operating Profit Annual1.93
Interest AnnualTBA
DepreciationTBA
Net Profit Annual1.93
Tax AnnualTBA

Biogen Pharmachem Industries Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning0.13
Cash Flow from Operations1.94
Cash Flow from Investing-2.06
Cash Flow from FinancingTBA
Cash Flow at the End0.02

Biogen Pharmachem Industries Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)15.13
PBIT Margin (%)15.13
PBT Margin (%)-741.17
Net PROFIT Margin (%)81.09
Return On Networth / Equity (%)0.52
Return On Networth /Employed (%)0.55
Return On Assets (%)0.81
Total Debt / Equity (X)TBA
Asset Turnover Ratio (%)0.01

Biogen Pharmachem Industries Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets AnnualTBA
Total Current Assets Annual0.09
Non Current Assets Annual56.73
Total Shareholders Funds Annual56.52
Total Assets Annual56.82

Biogen Pharmachem Industries Ltd Earning Calls

No Data Availabe

Get Your FAQs Right

As of Jan 15, 2025, Biogen Pharmachem Industries Ltd has a market capitalization of 69.18 Cr. Value Research classifies it as a Micro-Cap company.
Yes, Biogen Pharmachem Industries Ltd is debt-free with a debt-to-equity ratio of 0.00.
In FY 2024 , Biogen Pharmachem Industries Ltd recorded a total revenue of approximately 0 Cr marking a significant milestone in the company's financial performance.
Biogen Pharmachem Industries Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately -0.1% and -100.0% annually, respectively..
Biogen Pharmachem Industries Ltd's current PE ratio is 35.84.
Biogen Pharmachem Industries Ltd's ROCE averaged 1.4% from the FY ending March 2022 to 2024, with a median of 0.8%. It peaked at 3.4% in March 2024, reflecting strong capital efficiency over the period..
Biogen Pharmachem Industries Ltd's latest EBIT is Rs. 1.93 Cr, surpassing the average EBIT of Rs. 0.79 Cr over the 5 years..

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions